Cytomegalovirus (CMV) infection is the most common viral infection in liver transplant recipients responsible for life-threatening disease and allograft rejection. Overall, 18–29% of all liver transplant recipients develop CMV disease in the absence of prevention strategy. Therefore, efficient management of this life-threatening disease among liver transplant patients is need of the hour. This article outlines the prophylactic and preemptive therapy along with the pharmacotherapy of CMV disease in liver transplant recipients.
In absence of preventive antiviral strategy, CMV disease among liver recipients occurs most commonly during first 3 months of after transplantation. CMV infection leads to allograft rejection and immunosuppression. Such immunocompromised system of the patient further invites various opportunistic bacterial and viral infections. CMV infected recipients are also…
